Biopharma clinical development veteran to propel Opus’ AAV-b…
Born from the Foundation Fighting Blindness, the RD (Retinal Degeneration) Fund was created to help accelerate life-changing outcomes for people with retinal degenerations through direct mission related investments in therapeutic companies. The mission of the Foundation Fighting Blindness is to rapidly drive the research that will lead to preventions, treatments and cures for retinal degenerative diseases – including retinitis pigmentosa, age-related macular degeneration, Usher syndrome and the entire spectrum of retinal degenerative diseases. Together, these blinding conditions affect more than 200 million people throughout the world.
The RD Fund is changing how the world treats blinding retinal diseases.
Click here to download the January 2021 Outcomes & Outlook Report.
IN THE NEWS
03/08/2022
Foundation Fighting Blindness and InformedDNA Partner to Engage and…
Trial recruitment is enabled by the Foundation Fighting Blin…
02/15/2022
Opus Genetics Appoints Brian Leising Vice President, Manufacturing
20-year biopharma industry veteran to lead manufacturing for…
02/11/2022
ProQR Announces Top-Line Results from Phase 2/3 Illuminate Trial of…
ProQR has published the top-line results from the Phase 2/3 …
01/19/2022
Foundation Fighting Blindness Promotes Jason Menzo to President and…
Media Contact:
Chris Adams
Vice President, Marketing & Com…
01/06/2022
RD Fund Announces Series B Financing Behind SalioGen Therapeutics
Media Contact:
Chris Adams
410-423-0585
cadams@fightingblindnes…
01/05/2022
SalioGen Therapeutics Closes $115 Million Oversubscribed Series B F…
CAMBRIDGE, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) — SalioGen …
12/16/2021
ProQR Announces First Patients Dosed in Phase 2/3 Pivotal Trials of…
LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 16, 2021 (G…
12/09/2021
SparingVision Strengthens Leadership Team with the Appointment of D…
Paris, December 9, 2021 – SparingVision, a genomic medicine …
12/06/2021
Gyroscope Therapeutics Announces Appointment of Tony Adamis to Boar…
LONDON—(BUSINESS WIRE)—Dec 6, 2021—Gyroscope Therapeutics Ho…
12/02/2021
Startup spotlight: Opus Genetics, with $19M, works to advance cures…
by Jason Parker, WRAL TechWire
RALEIGH – Opus Genetics recen…
11/30/2021
Opus Genetics announces licensing of third program for inherited re…
Opus Genetics announced an agreement to license its third pr…